Clinical trials: Liver Diseases, Alcoholic
Non-alcoholic Fatty Liver Disease
Quantitative Detection Efficiency of UDFF for Nonalcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, affecting more than 25 % of the population globally.
- Trial name
- UDFF (NCT05802199)
- Testing
- Hepatic fat fraction and hepatic fibrosis
- Where
- 14 sites in China, Switzerland
- Volunteers
- 300 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Liver Fibrosis
Development of a Novel Biomarker for Liver Fibrosis
The overall aim of this study is to validate a quantitative digital tool for staging liver fibrosis in biopsies from chronic human liver diseases and then evaluate it prospectively in patients.
- Trial name
- NCT02348814
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Los Angeles
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Probiotics in the Treatment of NAFLD
Evaluate the effect of supplementation of probiotics on liver changes (histological and enzymatic), lipid profile and gut microbiota of patients with nonalcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver, Nonalcoholic, NAFLD
- Trial name
- NCT02764047
- Testing
- Probiotic
- Where
- Brazil
- Volunteers
- 58 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Type 2 Diabetes, Nonalcoholic Fatty Liver
Curcumin Supplement in Nonalcoholic Fatty Liver Patients
The purpose of this study is to investigate the effects of curcumin supplement on metabolic factors and hepatic fibrosis in nonalcoholic fatty liver patients with type 2 diabetes.
- Trial name
- NCT02908152
- Testing
- curcumin
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Non-Alcoholic Fatty Liver Disease
Prevention of NAFLD in Hispanic Children
This is a 2 year clinical trial testing an intensive intervention to reduce dietary sugars as a means to prevent non-alcoholic fatty liver disease (NAFLD) in pre-pubertal Hispanic children.
- Trial name
- NCT05292352
- Testing
- LFSD
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Emory University
Non-Alcoholic Fatty Liver Disease
The Clock Thickens: Morning or Evening Training for the Treatment of NAFLD?
The goal of this clinical trial is to investigate the different effect of morning and evening exercise training in individuals with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- TikTac (NCT05987748)
- Testing
- Exercise training
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Leiden University Medical Center
Alcoholic Hepatitis
HA35 Moderate Alcoholic Hepatitis (AH) Study
Eligible participants will be asked to take a placebo/treatment capsule for 90 days and participate in two in-person study visits, one at the start of the 90 days and the second at the completion of study supplement…
- Trial name
- NCT05018481
- Testing
- Sodium Hyaluronate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- The Cleveland Clinic
Nonalcoholic Fatty Liver
Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients
This study aims to identify the effect of adding TENS to the Mediterranean diet on appetite and liver enzymes in Nonalcoholic fatty liver patients.
- Trial name
- NCT07200934
- Testing
- Transcutaneous electrical stimulation (TENS), Mediterranean Diet
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Chronic Liver Disease
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)
- Trial name
- NCT06493799
- Testing
- LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC
- Where
- South Korea
- Volunteers
- 226 people
- Sponsor
- Green Cross Wellbeing
NAFLD, Liver Fibrosis
Different Doses of ZED1227 vs. Placebo in NAFLD
This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will…
- Trial name
- NormaliZED (NCT05305599)
- Testing
- ZED1227
- Where
- Germany
- Volunteers
- 186 people
- Sponsor
- Dr. Falk Pharma GmbH
NASH - Nonalcoholic Steatohepatitis
Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients
Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH) to determine the safety and tolerability of ascending single…
- Trial name
- PANASH (NCT03963921)
- Testing
- HepaStem
- Where
- 13 sites in Belgium, Bulgaria and 2 more
- Volunteers
- 23 people
- Sponsor
- Cellaion SA
Patients With Nonalcoholic Steatohepatitis
Evaluate the Efficacy, Safety and Tolerability of Fecal Microbiota Transfer for the Treatment of Patients With Nonalcoholic Steatohepatitis
The EMOTION study is a multicentric, double-blind, controlled, parallel-group, phase IIa randomized Clinical trial to evaluate the efficacy, safety and tolerability of TMF capsules for the treatment of patients with NASH.
- Trial name
- EMOTION (NCT05622526)
- Testing
- Group 1 or Experimental group, Group 2 or Control group
- Volunteers
- 96 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Non Alcoholic Fatty Liver Disease
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
There is preliminary evidence that Omega 3, a compound naturally found in fish oil, reduces the amount of fat stored in the liver and improves liver function.
- Trial name
- NCT01277237
- Testing
- Omacor, lactose tablet
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Edinburgh
Obesity, NASH - Nonalcoholic Steatohepatitis
Intragastric Balloon With Lifestyle Intervention vs. Lifestyle Intervention in Obese Patients With NASH
The primary objective of this study is to assess efficacy of intragastric balloon for weight loss in obese patients who also concurrently have NASH.
- Conditions
- Obesity, NASH - Nonalcoholic Steatohepatitis, Obesity, Morbid
- Trial name
- NCT03538236
- Testing
- Intragastric balloon, Lifestyle intervention
- Sponsor
- Johns Hopkins University
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- DPAILO-1 (NCT06344364)
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- 3 sites in Hong Kong, Spain
- Volunteers
- 1,241 people
- Sponsor
- PharmaNest, Inc
NAFLD - Nonalcoholic Fatty Liver Disease, NASH - Nonalcoholic Steatohepatitis
Curcumin for Pediatric Nonalcoholic Fatty Liver Disease
This is a single-center, randomized, double-blinded, placebo-controlled, parallel treatment groups phase 2a study of curcumin for pediatric nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT04109742
- Testing
- phosphatidylcholine-curcumin complex supplement
- Sponsor
- Columbia University
Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis
Genetic Studies of Non-Alcoholic Fatty Liver Disease
Background: Non-alcoholic fatty liver disease is the most common form of liver disease in the United States. It includes many conditions.
- Conditions
- Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT01629095
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Alcoholic Hepatitis
Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
Background: Alcoholic liver disease is one of the most important causes of chronic liver disease in this country. There is currently no treatment for chronic alcoholic liver disease other than abstinence.
- Trial name
- RCT SAMe (NCT00851981)
- Testing
- SAMe
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Loma Linda University
Cardiovascular Diseases, Non-Alcoholic Fatty Liver Disease
Smart Watch Insights for Prevention of Exacerbations and Enhance Rehabilitation - Movement Study
Aims of the study: 1. To deliver a scalable wellbeing programme to the local population of Imperial College Healthcare NHS Trust, focusing on movement. 2.
- Conditions
- Cardiovascular Diseases, Non-Alcoholic Fatty Liver Disease, Respiratory Disease, Diabetes
- Trial name
- SWIPER-MOVES (NCT06011356)
- Testing
- Smartwatch
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
NAFLD
Genetic-specific Effects of Fructose on Liver Lipogenesis
The primary goal of this study is to identify a set of genotypes that increase the risk for nonalcoholic fatty liver disease (NAFLD) and predispose individuals to increased de novo lipogenesis (DNL) and liver fat accumulation…
- Trial name
- NCT03783195
- Testing
- Sugar drink
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.